Oesophageal Cancer Clinical Trials

45 recruitingLast updated: June 18, 2026

There are 45 actively recruiting oesophageal cancer clinical trials across 22 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3. Top locations include Nashville, Tennessee, United States, Houston, Texas, United States, London, United Kingdom. Updated daily from ClinicalTrials.gov.


Oesophageal Cancer Trials at a Glance

45 actively recruiting trials for oesophageal cancer are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Nashville, Houston, and London. Lead sponsors running oesophageal cancer studies include Imperial College London, H. Lee Moffitt Cancer Center and Research Institute, and Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Browse oesophageal cancer trials by phase

Treatments under study

About Oesophageal Cancer Clinical Trials

Looking for clinical trials for Oesophageal Cancer? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oesophageal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oesophageal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 45 trials

Recruiting
Not Applicable

FAZA PETMRI Gastro-Oesophageal Study

Metastasized Gastro-Oesophageal Cancer
University Health Network, Toronto40 enrolled1 locationNCT04560036
Recruiting
Phase 2

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Breast CancerColorectal, CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals200 enrolled28 locationsNCT06695845
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled5 locationsNCT07419841
Recruiting
Phase 1

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Gastric Adenocarcinoma+10 more
IDEAYA Biosciences260 enrolled12 locationsNCT07277413
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Phase 2

BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

Gastroesophageal Cancer (GC)Pancreatic Cancer, Adult
Barbara Malene Fischer90 enrolled1 locationNCT07629609
Recruiting
Phase 1

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

Gastric (Stomach) CancerGastroesophageal CancerPancreatic Ductal Adenocarcinoma (mPDAC)
Dong-A ST Co., Ltd.51 enrolled3 locationsNCT07481357
Recruiting
Phase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Not Applicable

The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)

Gastroesophageal CancerIncurable Disease
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)196 enrolled22 locationsNCT06138223
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Breast CancerEsophageal CancerPancreatic Cancer+13 more
ModeX Therapeutics, An OPKO Health Company285 enrolled6 locationsNCT06239194
Recruiting
Phase 3

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Esophageal CancerOesophageal CancerSquamous Cell Esophageal Carcinoma
Sun Yat-sen University422 enrolled1 locationNCT05357846
Recruiting

Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)

Oesophageal Cancer
University Hospital Southampton NHS Foundation Trust160 enrolled14 locationsNCT06440174
Recruiting
Not Applicable

Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer

Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute80 enrolled2 locationsNCT06497569
Recruiting

Cancer Loyalty Card Study 2 (CLOCS-2)

Liver CancerPancreatic CancerOvarian Cancer+7 more
Imperial College London2,900 enrolled1 locationNCT06447064
Recruiting
Phase 1

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

Metastatic Breast CancerEndometrial CancerAdvanced Solid Tumor+6 more
Institut Paoli-Calmettes27 enrolled1 locationNCT05143970
Recruiting
Phase 2

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Gastric CancerGastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute36 enrolled1 locationNCT06109467
Recruiting

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Gastroesophageal CancerGastrostomyGastric
M.D. Anderson Cancer Center20 enrolled4 locationsNCT05205343
Recruiting
Phase 2

Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer

Gastric CancerGastroesophageal Cancer
Shanghai Zhongshan Hospital84 enrolled2 locationsNCT06468280
Recruiting

Sample Collection for Ongoing Research and Product Evaluation Study

Breast CancerLiver CancerPancreatic Cancer+9 more
Natera, Inc.9,600 enrolled1 locationNCT07318051
Recruiting
Phase 2

Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.

Squamous Oesophageal Cancer
Hebei Medical University Fourth Hospital142 enrolled1 locationNCT07266480